ClinicalTrials.gg
RecruitingNCT06055543Updated Sep 26, 2023

Impact of a New Plant-based High-energy Oral Nutritional Supplement on Nutritional Outcomes in Malnourished Patients

A Phase 4 interventional study of Fortimel in Malnutrition, Cancer and Inflammatory Bowel Diseases, sponsored by Danone Specialized Nutrition. Recruiting at 6 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-26.

Sponsored by Danone Specialized Nutrition (part of Danone) · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2024, 2 years 5 months ago, but the record still lists the study as recruiting.
  • Started Aug 2023; still recruiting 3 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Malnutrition by Danone — 2 open to participants now, 3 under way, none of them phase 3. Malnutrition · Danone.

Planned enrollment
Largest of 11
140 · median 73
Started
2023
with 1 other
Phase 4
Only one
of the 12
Registered
10th of 12
by date

Among the 12 studies in Malnutrition by Danone, this one has the largest planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2023, is the only one in phase 4, and was the 10th registered.

Malnutrition

1,278 studies on the registry are indexed under Malnutrition; 231 are open to participants now.

Browse Malnutrition studies →

Open to participants now

2 of the 12 studies in Malnutrition by Danone are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 150 Malnutrition studies recruiting now, 84 (56%) set no upper age limit and 44 (29%) stop at 75 or younger; 40 take children under 18; 30 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Malnutrition by Danone, or all of them as a file.
02

Study summary

This study aims to compare nutritional outcomes in terms of percentage of weight gain between a new planted-based high-energy ONS and a standard high-energy ONS with animal protein (cow's mil protein) in patients at malnutrition according to Global Leadership Initiative on Malnutrition (GLIM) criteria.

Read the detailed description

Due to the increasingly pressing need to develop an oral nutritional supplement (ONS) that does not contain animal ingredients, Fortimel PlantBased, suitable for patients with Disease-Related Malnutrition or who wish to avoid or reduce the consumption of animal products for dietary or lifestyle reasons, is being promoted. At the same time, it is also a therapeutic option to be considered in the population with allergy or intolerance to cow's milk protein. Therefore, the aim is to offer an adapted therapeutic nutritional solution that guarantees nutritional results that are not inferior than ONS with animal protein (cow's milk protein).

This study was designed as an open-label randomized controlled non-inferiority trial with two arms: a new planted-based ONS (Fortimel PlantBased) as the intervention arm and standard ONS (Fortimel Energy) as the control arm, both high-energy formulas (1.5 kcal/m; 200ml).

The study will be carried out in patients at malnutrition according to Global Leadership Initiative on Malnutrition (GLIM) criteria, who need to supplement their diet by taking a high-energy ONS for at least 12 weeks. These patients will be treated and follow-up by the Endocrinology and Nutrition services of 6 public hospitals in Spain.

03

Conditions studied

  • Malnutrition
  • Cancer
  • Inflammatory Bowel Diseases
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Hiv
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients ≥ 18 years old

    • Malnourished patients according to GLIM criteria
    • Patients with a high energy requirement (1.5kcal/ml) requiring the intake of 2 bottles of ONS per day for at least 12 weeks
    • Patients presenting any of the following clinical situations:
  • Elderly patients requiring oral nutritional support
  • Patients with digestive pathology including but not restricted to inflammatory bowel disease, short bowel syndrome, pancreatitis, without active malabsorption and maldigestion.
  • Chronic diseases such as , mild to moderate renal disease,
  • Oncologic patients with (ECOG) 0-1

    • Patients who have given their consent to participate
    • Patients who, in the opinion of the physician, have the capacity to answer the study questionnaires themselves or their caregivers

Exclusion criteria

Exclusion Criteria:

  • Patients who need ONS due to surgical or acute illness*

    • Patients with known intolerance or allergy to cow's milk, soya or peas
    • Patients with hyperthyroidism. Patients with uncontrolled hypothyroidism
    • Uncontrolled diabetic patients ( >8%)
    • Patients requiring enteral nutrition by tube or ostomy
    • Patients with moderate and serious renal insufficiency \< 30ml/min/1,73 m2
    • Patients who have value creatinine:

      • 1,70 mg/dl - 150,31umol/L Men
      • 1,50 mg/dl - 132,63umol/L Women
    • Patients with levels of \<10 g/dl, transferrin \<150 mg /dl
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
140 participants (estimated)

Study arms

  • Active comparator
    Fortimel Energy

    Control: high-energy ONS 1.5 Kcal/m 200ml for 90 days

    Dietary Supplement: Fortimel

  • Experimental
    Fortimel PlantBased

    Intervention: high-energy ONS 1.5 Kcal/m 200ml for 90 days

    Dietary Supplement: Fortimel

Interventions

  • Dietary supplementFortimel

    2 bottles/day of the high energy ONS

06

What researchers measure

Primary outcomes

  1. Change in weight

    Change in weight percentage

    Time frame: Changes between baseline and final visit (12 weeks).

  2. Improvement in nutritional status

    Improvement in nutritional status according to the GLIM criteria. A change in classification category from grade 2 of malnutrition to grade 1 or not meet GLIM criteria, as well as a change from grade 1 to not meet GLIM criteria are considered an improvement.

    Time frame: From the baseline to the final visit (12 weeks)

Secondary outcomes

  1. Change in muscle strength

    Measured by dynamometry

    Time frame: From the baseline to final visit (12 weeks)

  2. Change in calf circumference

    Time frame: From baseline to final visit (12 week)

  3. Percentage of compliance

    Taking into account the number of bottles per day taken, the ml of product and the ml left over.

    Time frame: During the study follow up

  4. Changes in the gastrointestinal symptom scale (GSRS)

    Total score

    Time frame: From the baseline to final visit (12 week)

  5. ONS Satisfaction

    Patients satisfaction taking ONS will be considered if a patient indicates a score of at least 8 points for overall satisfaction question.

    Time frame: Final visit (12 week)

07

Study locations

6 of 6 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for May 2024, 9 months after the start.

Of 17 phase 4 interventional studies under Malnutrition, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 49. This study's planned 9 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2023
First posted
Sep 26, 2023
StartActual
Aug 9, 2023
Primary completionEst.
May 31, 2024
CompletionEst.
May 31, 2024
Last update
Sep 26, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06055543
Responsible party
Sponsor
First posted
Sep 26, 2023
Start date
Aug 9, 2023
Primary completion
May 31, 2024 (estimated)
Completion
May 31, 2024 (estimated)
Last update
Sep 26, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion